Lung fibrosis is a disease that carries poor prognosis and high mortality rate. The mechanisms of fibrosis may include disordered wound healing, infiltration with inflammatory cells and fibroblasts and release of reactive oxygen species and growth factors. The aim of this study was to assess the effect of metformin (Biguanide) on lung fibrosis induced by bleomycin and to clarify the molecular mechanisms of this effect. Sixty male Wistar rats were divided into 6 equal groups as follows: control group; bleomycin for 4 weeks group; metformin prophylactic group; bleomycin for 6 weeks group; metformin therapeutic group and metformin alone group. The weight of rats was recorded. Bronchoalveolar lavage (BAL) was analyzed for total and differential leukocyte count, tumor necrosis factor alpha (TNF-α) and transforming growth factor beta 1 (TGF-β1). Lung tissue hydroxyproline, malondialdehyde and superoxide dismutase were measured. Also, parts of the lungs were subjected to histopathological and immunohistochemical examination for nuclear factor kappa B (NF-κB). Metformin used prophylactically improved the histopathological picture and NF-κB immunostaining and decreased the oxidative stress, TGF-β1, TNF-α and BAL cellularity. When used therapeutically, metformin decreased oxidative stress and TGF-β1 but didn't improve TNF-α, the histopathological picture and NF-κB immunostaining. In conclusion, metformin has ameliorative effect on bleomycin-induced lung fibrosis when used prophylactically better than when used therapeutically.. 
INTRODUCTION
Idiopathic lung fibrosis is an interstitial lung disease which is characterized by replacement of the normal lung tissue with fibrous tissue due to imbalance between matrix production and degradation that ultimately ends in respiratory failure and death. It carries poor prognosis, high mortality rate and limited therapeutic options due to complex pathogenesis [1] .
Up till now, no exact mechanism fully explains the pathogenesis of the fibrotic process encountered in bleomycin-induced pulmonary fibrosis. The old theory of inflammatory alveolitis followed by fibrosis had been criticized due to failure of anti-inflammatory drugs to attenuate fibrosis and unfortunately exacerbated the ongoing fibrosis [2] . The new paradigm states that multiple factors may play a role in initiation and progression of fibrotic process. It is now considered a state of impaired wound healing due to repetitive micro injuries which result in altered microenvironment of alveolar epithelial, endothelial and mesenchymal cells through various growth factors, cytokines, and inflammatory cells, which leads to activation of fibroblasts and resistance to apoptosis, so healing process becomes disrupted and fibrosis ensues [3] .
Bleomycin is an anti-cancer drug which is effective against many types of tumors, but this effectiveness is limited due to development of dose dependent lung fibrosis, which occurs due to enhanced oxidative stress that leads to inflammatory response and activation of fibroblasts through various cytokines and growth factors.
Bleomycin is the most widely used model for studying lung fibrosis mechanisms and evaluating therapy; as it is well characterized, clinically relevant and develops fibrosis more rapid than other models [4] .
Many studies have evaluated the protective effect of drugs in bleomycin model, but this may be misleading; as it doesn't lead to clinically therapeutic benefit, so to gain the utmost benefit of the tested drug, it must be given after establishment of fibrosis that becomes evident after inflammation subsides, and this occurs at day 15 after bleomycin administration [5] .
Metformin is one of biguanides that are recommended as first line oral therapy of type 2 diabetes mellitus. In addition, it has a therapeutic potential in diabetic nephropathy, cardiovascular diseases, nonalcoholic fatty liver disease, inflammatory disorders and the prevention or treatment of cancer [6, 7] . Recently, metformin has been studied for its efficacy against tissue remodeling in the lung [8] . Currently, few studies have been conducted to elucidate the preventive role of metformin in attenuating lung fibrosis [9, 10] , while no studies were conducted to test the therapeutic potential of metformin. The aim of this study was to assess the effect of metformin (Biguanide) on lung fibrosis induced by bleomycin and to clarify the molecular mechanisms of this effect.
Materials & Methods
All the experiments in this study were conducted in accordance with the U.S. National
Institutes of Health Guidelines for the Care and
Use of Laboratory Animals. This study was approved by the Research Ethics Committee of faculty of medicine, Tanta University (Approval code 2066/9/13). Animal handling was followed according to Helsinki declaration of animal ethics.
Drugs used
Bleomycin 15 U/vial of (Cipla, India) equivalent to 15mg/vial white powder freely soluble in saline prepared by reconstitution of powder with 3ml saline to a final concentration of 5mg/ml. Metformin (Glucophage ® ) of Merck 500 mg/tablet was prepared by dissolving tablet in distilled water to reach a final concentration of 100 mg/ml.
Animal model
Sixty male Wistar rats, weighing initially 90-120 gm were used in this study. They were maintained on a standard laboratory diet and tap water and exposed to a 12/12 h light dark cycle.
The animals were randomly divided into 6 equal groups as follows: Group 1 (control group), Group 
Experimental protocol

Assessment of BAL TGF-β1 and TNF-α
Transforming growth factor beta-1 (TGF-β1) was determined by using BOSTER 
Histopathological examination
The left lungs were immediately fixed in 
Assessment of NF-kB (p65) immunostaining
The sections were immunostained with primary antibody polyclonal IgG to rat NF-κB p65 
Statistical analysis
Statistical analysis was carried out using Graph Pad Prism version 5. Data were expressed as mean ± standard error of mean (SEM), while nonparametric data were presented as median (minmax). Multiple comparisons were performed using one-way ANOVA followed by Tukey-Kramer as a post hoc test. For histology scoring and total leukocytic count, Mann Whitney test was used. Pvalues less than 0.05 were considered statistically significant.
Results
Effect of different treatments on weight gain rate
The results of weight gain rate are shown in ( 
Effect of different treatments on total and differential cell count in BALF
Histopathological results
In group 2, there was significant increase fibrosis score (median 5) ( Figure 5B ) compared to control group (median 0) ( Figure 5A) (p<0.01) . In group 3, there was significant decrease in fibrosis score (median 2) ( Figure 5C ) compared to group 2 (p<0.01). In group 4, there was significant increase in fibrosis score (median 6)(figure 5D) compared to control group (median 0) (p<0.01). In group 5, there was non-significant change in fibrotic score (median 4) ( Figure 5E ) compared to group 4 (p>0.05(. In group 6, there was non-significant change in fibrosis score (median 0.5) ( Figure 5F ) compared to the control group (median 0) (p>0.05). 
Effect of different treatments on NF-κB (p65) immunostaining
Discussion
In the present study, bleomycin was denoted by Hu et al. [28] and Yasuda et al. [29] .
Yet in the present study, it didn't affect weight gain when given alone to rats.
Therapeutic not prophylactic metformin led to prevention of weight loss induced by bleomycin. Administration of prophylactic not therapeutic metformin decreased total cell count.
However, at differential level there was no difference between the two groups as both decreased neutrophils and elevated macrophages ,but no effect was observed on elevated lymphocytes and this is in agreement with the notion that lymphocytosis may indicate good prognosis and response to therapy [30] . Zmijewski et al. [31] reported that metformin inhibited 
Conclusion
Metformin when used prophylactically is more beneficial in reduction of bleomycin-induced lung fibrosis than when used therapeutically. This effect may be due to reduction of NF-κB, TNF-α and TGF-β1 together with amelioration of the oxidative stress and reduction of the inflammatory cells.
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